Fear of adverse events should not prevent the use of appropriate antihypertensive drug therapy

William J. Kostis, Javier Cabrera

Research output: Contribution to journalEditorialpeer-review

Abstract

A recent publication reported that Systolic Blood Pressure Intervention Trial participants with 10-year cardiovascular disease risk less than 11.5% derived more harm than benefit from intensive treatment. The authors consider that serious adverse events (SAEs) are of equal importance to that of either all-cause death or the primary composite outcome (myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes). Under this premise, one death would correspond to 2.7 SAEs and a primary outcome to 1.8 SAEs overall, and to be between 6 and 18 times as important as an SAE in the intensive treatment group. In our opinion, patient utility should be considered when clinical decisions are made for the treatment of hypertension.

Original languageEnglish (US)
Pages (from-to)756-758
Number of pages3
JournalJournal of the American Society of Hypertension
Volume12
Issue number11
DOIs
StatePublished - Nov 2018

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Keywords

  • Cardiovascular clinical outcomes
  • mortality
  • serious adverse event

Fingerprint

Dive into the research topics of 'Fear of adverse events should not prevent the use of appropriate antihypertensive drug therapy'. Together they form a unique fingerprint.

Cite this